Precision Medicine in Oncology /

Bibliographic Details
Call Number:Libro Electrónico
Other Authors: Aydogan, Bulent (Editor), Radosevich, James A. (Editor)
Format: Electronic eBook
Language:Inglés
Published: Wiley-Blackwell, 2020.
Edition:1st.
Subjects:
Cancer > Radiotherapy.
Radiation Oncology
Cancer > Radiothérapie.
Cancer > Radiotherapy
Online Access:Texto completo
Table of Contents:
  • Cover
  • Title Page
  • Copyright Page
  • Contents
  • List of Contributors
  • Preface
  • List of Abbreviations
  • Chapter 1 Genomic Strategies for Personalized Cancer Therapy
  • 1.1 Introduction
  • 1.1.1 Definition of Precision Medicine in Oncology
  • 1.1.2 DNA and RNA Sequencing Techniques
  • 1.2 Precision Medicine in Specific Tumors
  • 1.2.1 Lung Cancer
  • 1.2.1.1 Adenocarcinoma
  • 1.2.1.2 Squamous Cell Carcinoma
  • 1.2.1.3 Small-Cell Lung Carcinoma (SCLC)
  • 1.2.1.4 Epidermal Growth Factor Receptor (EGFR) Mutations
  • 1.2.1.5 Anaplastic Lymphoma Kinase (ALK)
  • 1.2.1.6 BRAF, ROS1, MET
  • 1.2.1.7 KRAS
  • 1.2.1.8 Other: RET, NTRK
  • 1.2.2 Head and Neck Cancers
  • 1.2.2.1 HPV-Positive Cancers
  • 1.2.2.2 HPV-Negative Cancers
  • 1.2.2.3 Targeting the Epidermal Growth Factor Receptor (EGFR) Pathway
  • 1.2.2.4 Thyroid Cancers
  • 1.2.2.5 Other Targets
  • 1.2.3 Hematological Malignancies
  • 1.2.3.1 Lymphoma
  • 1.2.3.2 Leukemia
  • 1.2.3.3 Myelodysplastic Syndrome
  • 1.2.4 Gynecologic Malignancies
  • 1.2.4.1 Cervical
  • 1.2.4.2 Uterine
  • 1.2.4.3 Ovarian
  • 1.2.5 Melanoma
  • 1.2.6 Gastrointestinal Malignancies
  • 1.2.6.1 Gastroesophageal Cancers
  • 1.2.6.2 Colorectal Cancers
  • 1.2.7 Breast Cancer
  • 1.2.7.1 Basal-Like, or Triple Negative Breast Cancer
  • 1.2.7.2 Luminal A/B, or Hormone Positive
  • 1.2.7.3 HER2 Positive Breast Cancer
  • 1.2.7.4 Immunotherapy
  • 1.2.7.5 Germline Testing in Breast Cancer
  • 1.2.7.6 Conclusion
  • 1.2.8 Genitourinary Malignancies
  • 1.2.8.1 Prostate Cancer
  • 1.2.8.2 Renal Cell Cancer (RCC)
  • 1.2.8.3 Urothelial Cancers
  • 1.2.9 Pediatric Cancers
  • 1.2.9.1 Introduction
  • 1.2.9.2 Leukemia and Lymphoma
  • 1.2.9.3 Central and Peripheral Nervous System Tumors
  • 1.2.9.4 Bone and Soft Tissue Sarcomas
  • 1.2.9.5 Other Embryonal Tumors
  • 1.2.9.6 Conclusion
  • 1.2.10 Cancers of Unknown Primary Origin
  • 1.2.10.1 Diagnosis
  • 1.2.10.2 Gene Expression Profiling
  • 1.2.10.3 Mutational Testing with Next-Generation Sequencing (NGS)
  • 1.2.10.4 Treatment
  • 1.3 Biomarkers for Immunotherapy of Cancer
  • 1.3.1 PD-L1
  • 1.3.2 Soluble PD-L1 (sPD-L1)
  • 1.3.3 Combined Positive Score (CPS)
  • 1.3.4 Tumor Microenvironment
  • 1.3.5 Tumor Mutational Burden (TMB)
  • 1.3.6 Microsatellite Instability (MSI)
  • 1.3.7 MMR Deficiency
  • 1.3.8 Peripheral Blood Absolute Neutrophil Count/Absolute Lymphocyte Count
  • 1.3.9 Microbiome
  • 1.4 Clinical Trial Design in the Era of Precision Oncology
  • 1.5 Ethical, Legal, and Social Issues of Precision Oncology
  • 1.5.1 Ethical Issues
  • 1.5.2 Legal Issues
  • 1.5.3 Social Issues
  • 1.6 Databases, Data Sharing, and Challenges of Precision Oncology
  • References
  • Chapter 2 Blood-Based Biomarkers for the Diagnosis and Prognosis of Cancer
  • 2.3 Circulating Proteins as Biomarkers
  • 2.4 Circulating Long Non-coding RNAs as Biomarkers
  • 2.5 Circulating miRNAs as Biomarkers
  • 2.6 Circulating Autoantibodies as Biomarkers
  • 2.7 Circulating Tumor DNA as Biomarkers

Similar Items